Skjesol Ingunn, Tritter Jonathan Q
Faculty of Nursing and Health Sciences, Nord University, Finn Christiansens veg 1, 7804 Namsos, Norway.
Faculty of Social Sciences, Nord University, Høgskolevegen 27, 7600 Levanger, Norway.
Health Policy Technol. 2022 Jun;11(2):100635. doi: 10.1016/j.hlpt.2022.100635. Epub 2022 Apr 30.
To describe the evolution of the national vaccination programme in Norway and how changes in national policy informed by risk and equity shaped international vaccine debates, public trust and vaccine hesitancy.
Documentary analysis of publicly available statistics, government documents and media sources.
Process equity founded on social solidarity was central to the approach taken to vaccination in Norway but within the context of a very low level of COVID-19 Infection.
In the context of Norway with very low levels of infection, the risks associated with vaccine side effects were of a similar order to the risk of infection which led to an early decision to exclude the AstraZeneca vaccine and limit access to the Janssen vaccine. Public trust in the way the state managed the changes in the vaccination programme resulted in very limited public resistance to the vaccine programme, high levels of vaccine uptake and an acceptance of delays associated with the exclusion of two approved vaccines. Vaccination rates among Norwegian residents born in Eastern Europe were significantly lower than both foreign born and Norwegian born residents.
描述挪威国家疫苗接种计划的演变，以及基于风险和公平的国家政策变化如何影响国际疫苗辩论、公众信任和疫苗犹豫情绪。
对公开的统计数据、政府文件和媒体来源进行文献分析。
基于社会团结的过程公平是挪威疫苗接种方法的核心，但处于新冠病毒感染率非常低的背景下。
在挪威感染率非常低的背景下，疫苗副作用相关风险与感染风险处于相似水平，这导致了早期决定排除阿斯利康疫苗并限制杨森疫苗的使用。公众对国家管理疫苗接种计划变化方式的信任导致公众对疫苗计划的抵制非常有限、疫苗接种率很高，并且接受了与排除两种获批疫苗相关的延迟。在东欧出生的挪威居民的疫苗接种率明显低于外国出生和挪威出生的居民。
